Findings of a Study Comparing Standard Radiation to IMRT in Endometrial, Cervical Cancer

Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Recent studies reported a potential reduction in stem cell yields in patients who were exposed to daratumumab prior to stem cell mobilization.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Patients aged 80 years or older and/or considered frail who received acalabrutinib for chronic lymphocytic leukemia experienced toxicities consistent with prior trials.

At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.